Últimas noticias sobre Aspira Womens Health (NASDAQ:AWH) Bolsa

Aspira Womens Health

Allied World Assurance

Allied World Assurance Company Holdings, AG

NYSE

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Aspira Women's Health Inc. - Common Stock

Aspira Womens Health Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Aspira Women's Health Inc. ("Aspira") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlighting data demonstrating that a multimodal assay combining miRNA with protein biomarkers, age, and menopausal status offered the most accurate classification of patients with an adnexal mass for the identification of early-stage ovarian cancer.

Biotech

News

General

Aspira Women's Health Announces Publication Of Data Demonstrating Performance Of Its In-Development Blood Test For The Assessment Of Malignancy Risk In Patients With An Adnexal Mass

Alliance Global Partners analyst Ben Haynor maintains Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) with a Buy and lowers the price target from $7 to $5.5.

Price Target

Analyst Ratings

Alliance Global Partners Maintains Buy on Aspira Womens Health, Lowers Price Target to $5.5

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. The company reported quarterly sales of $2.423 million which missed the analyst consensus estimate of $2.600 million by 6.81 percent. This is a 2.73 percent decrease over sales of $2.491 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Aspira Womens Health Q2 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $2.423M Miss $2.600M Estimate

Offerings

Aspira Women's Health Inc Files For Offering Of Up To 2.5M Shares By The Selling Stockholders

WIIM

Aspira Women's Health shares are trading higher after the company announced that preliminary OvaWatch volume during Q2 2024 grew 24% quarter-over-quarter to 1,307 units.

Preliminary OvaWatch&#xAE; volume during Q2 2024 grew 24% over the prior quarter to 1,307 units &nbsp;
Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units
AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary second quarter 2024 OvaSuite product volume and highlights.
Preliminary Second Quarter 2024 Product Volume and Highlights
<ul>
<li>The number of OvaWatch tests performed during the second quarter ended June 30, 2024, was 1,307, an increase of 48%, compared to the 884 tests in the same period last year, and an increase of 24% to the 1,052 tests sequentially. &nbsp;</li>
<li>The number of OvaSuite tests performed during the second quarter ended June 30, 2024, was 6,471, an increase of 3% compared to the 6,289 tests in the same period last year, and an increase of 11% to the 5,829 tests in the first quarter. &nbsp;</li>
<li>The Company was notified that it has been selected as a finalist for an ARPA-H grant to support further development of its protein + microRNA blood test for endometriosis. Announcement of the final grant award recipients is anticipated in the second half of 2024. &nbsp;</li>
<li>The Company has completed a comprehensive analysis of its biobank and has identified up to 70,000 serum, plasma, and whole blood samples that are available for secondary research. The Company is exploring opportunities to create non-dilutive sources of cash through related collaborations.</li>
</ul>
 &nbsp;

Guidance

Aspira Women's Health Announces Preliminary OvaWatch Volume During Q2 2024 Grew 24% QoQ To 1,307 Units; Preliminary OvaSuite Volume During Q2 2024 Grew 11% QoQ To 6,471 Units

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 12.32% to $0.41. The market value of their outstanding shares is at $10.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock declined by 15.5% to $1.01 during Thursday's pre-market session. The market value of their outstanding shares is at $25.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 11.11% to $0.35. The market value of their outstanding shares is at $15.8 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares decreased by 9.1% to $2.5. The market value of their outstanding shares is at $101.3 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 8.82% to $16.86. The company's market cap stands at $23.7 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) shares decreased by 8.32% to $3.42. The market value of their outstanding shares is at $120.1 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock decreased by 7.77% to $0.95. The market value of their outstanding shares is at $11.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABSI

AMIX

CNSP

DHAI

Euda Health Holdings Limited - Ordinary Shares

EUDA

GANX

MEDS

SLRX

SNTI

TRAW

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Aspira Women's Health shares are trading higher. The company announced a private placement equity financing of $1.935 million.

The company announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1.264 million&nbsp;shares of its common stock&nbsp;and warrants to purchase an equal number of shares of Common Stock at a combined offering price of&nbsp;$1.53&nbsp;per share and warrant through a private placement financing.
The warrants will be exercisable for three years after date of issuance and have an exercise price of&nbsp;$2.25&nbsp;per share.
Net proceeds from the Offering will support Aspira&#39;s ongoing commercial activities as well as general corporate purposes and working capital.

Aspira Women's Health Reveals Private Placement Equity Financing Of $1.935M

Monthly OvaSuiteSM&nbsp;product volume grew by more than 26% in May compared to January &nbsp;
Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite
Cash used in operations guidance for 2024 expected to be lowered
AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024.

Aspira Women's Health Providing A Downward Revision Of The 2024 Cash Used In Operations Guidance During Q2 2024 Earnings Call

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 35 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $2.15 million which missed the analyst consensus estimate of $2.41 million by 10.66 percent. This is a 7.04 percent decrease over sales of $2.32 million the same period last year.

Aspira Womens Health Q1 EPS $(0.39) Misses $(0.34) Estimate, Sales $2.15M Miss $2.41M Estimate

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. &nbsp;
The first manuscript, entitled "<a href="https://www.globenewswire.com/Tracker?data=RVFAd9d07MWxF_aCnjnkuk9rdibrdtYyZriUr87SnSBkzxNPM2_w4mosj26PRN4wHii71gNXCyMUgBKCF9v6M3fxDjrYsGb4eVh2QwEoziyLHBcTlxDTVY2a_qLbAPCTVumhzA9a7-t8dT2f-Hj3fst3cQ5w48No-jMxFfOHt_cj7jVRFC5BmbeEvl9SPf7qWbxEAf0rP_uo54crfsoCXmegQZG6CxWVdsjDY5Sy9VikAfMUACSv4t6rs_vnFzOSfr3KiIXt5AfNobtVSUah7u_cXZczJF2gOBwO08JV8to=">Ovarian Cancer Surgical Consideration is Markedly Improved by the Neural Network Powered-MIA3G Multivariate Index Assay</a>" was published in the peer-reviewed journal Frontiers of Medicine on May 2, 2024. The findings of this study demonstrate that use of OvaWatch&#xAE; to stratify risk in patients with an adnexal mass might help to reduce surgical backlogs and unnecessary surgical referrals.
The second manuscript, entitled: "<a href="https://www.globenewswire.com/Tracker?data=YhKQaHmMGxUNYNjQuaD8nUKbfzEUez7LoIZMQZcu2EwbpsBpVqZnRSwpzFfpXP-DY6O5pBZEP2eTR1rIQZ5B1lkjX2UGUlymHDtDKkITVCUth-6B-XcKDFNmseHaiTrDePsgwtK4AioZoh55Etc7vasJIam9qf7NtWpoii000pKrJXh7I_L6qa7YBwiTs-hbAkOj5DwM-xtevJ-TAlbLljasLhSLECRN7TyhatLsk5RcoB6cCgSSP_6PoHesT6Vi6BozgEctPPD0LRjTkwJUXur1Rh3QCsW0AvTMguzAhO5x57BtD21yQtjN9ycw2fbi">Neural Network-derived Multivariate Index Assay Demonstrates Effective Clinical Performance in Longitudinal Monitoring of Ovarian Cancer Risk</a>" was published in the journal Gynecologic Oncology on May 3, 2024. The findings of this study demonstrate that OvaWatch could be an effective tool for the monitoring of ovarian cancer risk over time in women with indeterminate or low risk adnexal masses. Based on common practice for adnexal mass management and consistent with the study, OvaWatch can be drawn by the provider every three to six months for active surveillance of an adnexal mass.
"Today, we mark the publication of additional clinical data to support the use of OvaWatch for the assessment of ovarian cancer risk for women with an adnexal mass," said Nicole Sandford, Chief Executive Officer of Aspira. "We believe these studies will help accelerate the adoption of OvaWatch for initial and ongoing monitoring of patients to provide an alternative to surgical intervention for lower risk cases. Clinicians have long sought a better tool to develop an appropriate care plan for these women, and OvaWatch provides it."
"The publication of these manuscripts, along with last week's announcement to make OvaWatch available for testing over time, is the latest example of Aspira keeping its promises to our stakeholders. We are well on our way to achieving our mission to improve outcomes for women with gynecologic diseases."
The total addressable market for OvaSuite, the company's portfolio of ovarian cancer risk assessment blood tests, is 2.0-3.0 million tests per year.

Aspira Women's Health Announces Publication Of Two OvaWatch Peer-Reviewed Manuscripts

Cantor Fitzgerald analyst Ross Osborn reiterates Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) with a Neutral and maintains $3.3 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Aspira Womens Health, Maintains $3.3 Price Target

Cantor Fitzgerald analyst Ross Osborn maintains Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) with a Neutral and lowers the price target from $4 to $3.3.

Cantor Fitzgerald Maintains Neutral on Aspira Womens Health, Lowers Price Target to $3.3

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 45.45 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $2.13 million which missed the analyst consensus estimate of $2.54 million by 16.14 percent. This is a 1.07 percent decrease over sales of $2.15 million the same period last year.

Aspira Womens Health Q4 EPS $(0.30) Beats $(0.45) Estimate, Sales $2.13M Miss $2.54M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Aspira Womens Health will report an earnings per share (EPS) of $-0.45. 
Aspira Womens Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 8.6% drop in the share price the next day.
Here's a look at Aspira Womens Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.51</td>
<td>-0.47</td>
<td>-0.75</td>
<td>-0.9</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.28</td>
<td>-0.75</td>
<td>-0.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-8.0%</td>
<td>-7.000000000000001%</td>
<td>-16.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711551696_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Aspira Womens Health were trading at $3.5 as of March 26. Over the last 52-week period, shares are down 39.24%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AWH/earnings">To track all earnings releases for Aspira Womens Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Aspira Womens Health's Earnings

<h3>Gainers</h3>
<ul>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. </li>
<li>Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) shares moved upwards by 14.0% to $35.99. The market value of their outstanding shares is at $5.2 billion. </li>
<li>argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) stock moved upwards by 13.24% to $404.22. The market value of their outstanding shares is at $23.9 billion. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) shares moved upwards by 11.79% to $0.39. The company's market cap stands at $7.5 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock rose 10.79% to $3.85. The company's market cap stands at $39.7 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock moved upwards by 10.6% to $6.05. The market value of their outstanding shares is at $23.0 million. As per the press release, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) shares decreased by 33.4% to $29.75 during Thursday's pre-market session. The company's market cap stands at $762.9 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock fell 16.22% to $1.55. The company's market cap stands at $53.6 million. The company's, Q4 earnings came out today. </li>
<li>Immatics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>) shares declined by 15.49% to $10.18. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock declined by 13.43% to $0.38. The market value of their outstanding shares is at $4.4 million. </li>
<li>Exscientia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) shares declined by 12.69% to $5.99. The company's market cap stands at $748.3 million. As per the press release, Q4 earnings came out today. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock decreased by 12.43% to $2.89. The company's market cap stands at $3.9 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

ARGX

AVGR

BPTS

CMAX

EXAI

IMTX

IMVT

TRML

VIRI

YTEN

First Lady&nbsp;Jill Biden&nbsp;unveiled a significant milestone in the White House Initiative on Women&#8217;s Health Research by announcing $100 million in federal funding for research and development for women&#8217;s health.&nbsp;
This move represents a crucial step in addressing the historical underfunding and lack of research into women&#8217;s health issues, a concern highlighted by Biden.
The funding stems from the Advanced Research Projects Agency for Health (ARPA-H), a component of the federal Department of Health and Human Services.&nbsp;
The initiative marks a pivotal moment in advancing solutions to women&#8217;s health problems, the Washington Post&nbsp;<a target="_blank" href="https://www.washingtonpost.com/politics/2024/02/21/jill-biden-research-womens-health-arpah-shriver/889c4020-d0a0-11ee-ac8b-765284b5203e_story.html" rel="noreferrer noopener">noted</a>, aiming to reshape the research landscape and secure increased funding.
President Joe Biden&nbsp;established the Advanced Research Projects Agency for Health in 2022 as part of his &#8220;unity agenda,&#8221; focusing on tackling health challenges.&nbsp;
The newly announced ARPA-H Sprint for Women&#8217;s Health will kick off in the coming weeks, encouraging innovative ideas to propel groundbreaking research and development in women&#8217;s health.
During an appearance in Cambridge, Massachusetts, the First Lady emphasized the lack of awareness among women regarding their health due to historical underfunding in research.&nbsp;
Have a look at the stocks:
<a target="_blank" href="https://www.benzinga.com/quote/HOLX" rel="noreferrer noopener">Hologic Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) markets women&#8217;s diagnostics, including skeletal health and scanner systems and diagnostic products related to Sexually Transmitted Infections.
<a target="_blank" href="https://www.benzinga.com/quote/DARE" rel="noreferrer noopener">Daré Bioscience Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) markets Xaciato (Clindamycin Phosphate) Vaginal Gel 2% indicated for bacterial vaginosis in females 12 years of age and older. The company also has several products under development for contraception, sexual &amp; vaginal health, fertility, and menopause.
<a target="_blank" href="https://www.benzinga.com/quote/awh" rel="noreferrer noopener">Aspira Women&#8217;s Health Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is focused on ovarian cancer diagnosis. The company developed OvaSuite, a blood test for ovarian cancer, to use with ultrasound checkups (OvaWATCH).
<a target="_blank" href="https://www.benzinga.com/quote/OGN" rel="noreferrer noopener">Organon Inc.&#8217;s</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) portfolio and pipeline are focused on bacterial vaginosis, breast cancer, contraception, endometriosis, fertility, hysterectomy, menopause, osteoporosis, polycystic ovarian syndrome, and postpartum hemorrhage.
<a target="_blank" href="https://www.benzinga.com/quote/FEMY" rel="noreferrer noopener">Femasys Inc&#8217;s&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) FemBloc permanent birth control in late-stage clinical development as the first and only non-surgical, in-office, permanent birth control method. Femasys&#8217; FDA-approved FemaSeed Intratubal Insemination is an infertility treatment designed to deliver sperm directly where conception occurs.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Jill Biden Photo By Gage Skidmore On Flickr

Government

Health Care

Financing

FEMY

HOLX

First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks

Aspira Women's Health Inc. ("Aspira") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024. &nbsp;
"Endometriomas are among the most common forms of endometriosis, impacting millions of women. The presentation of data that is foundational to our EndoCheckSM offering at this distinguished conference is a major milestone for our plan to launch the first noninvasive diagnostic test for this debilitating disease," said Nicole Sandford, Chief Executive Officer of Aspira.
Details of the poster presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Poster Title:</td>
<td>A Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis</td>
</tr>
<tr>
<td>Author:</td>
<td>Todd Pappas, Ph.D., Vice President of R&amp;D at Aspira</td>
</tr>
<tr>
<td>Abstract #:</td>
<td>2066</td>
</tr>
<tr>
<td>Poster #:</td>
<td>LB-F-04</td>
</tr>
<tr>
<td>Date:</td>
<td>March 15, 2024</td>
</tr>
<tr>
<td>Time:</td>
<td>9:00 – 10:00 am PST / 12:00 –1:00 pm EST</td>
</tr>
<tr>
<td>Session:</td>
<td>Late Breaking</td>
</tr>
</tbody>
</table>
</figure>
The abstract was co-authored by Aspira's Research and Development team and the Oxford Endometriosis Care and Research (CaRe) Centre, a collaboration between Oxford University Hospitals and the Nuffield Department of Women's Reproductive Health of the University of Oxford. The poster will be available on the Company's investor relations website after it is presented at the conference.
SRI, established in 1953, is an international society with over 900 members representing 35 countries. SRI strives to advance reproductive health for all through outstanding basic, translational, and clinical science; training and mentoring future generations of investigators; and by promoting excellence in reproductive sciences globally (<a href="https://www.globenewswire.com/Tracker?data=8juZil7newKOV3-vx2huH2TcDL51YiGkx4EE7Pa7ky1nzUE_1zcyd3EFDwXHOrlQs7pOfzlu5k8e2BnJ4QV6bNQrJUwHc88ra3DzFuA89Fk=">www.sri-online.org</a>).

Events

Aspira Women's Health Announces Late-Breaking Poster Presentation At The Upcoming 71st Annual Scientific Meeting For The Society For Reproductive Investigation

An announcement from Aspira Women's Health (AWH) is now available. Aspira Women's Health Inc. has announced significant commercial and operational ...

Aspira Women's Health Reveals Major Commercial Updates

Aspira Women's Health (AWH) has shared an announcement. Aspira Women's Health Inc. has terminated Dr. Torsten Hombeck as CFO due to a personal civi...

Aspira Women's Health CFO Replaced, CEO Takes Interim Role

Aspira Women's Health announces $1.935M private placement equity financing

Aspira Women's Health reports Q2 OvaSuite product volume

Aspira Women's Health files to sell 2.5M shares of common stock for holders

Aspira Women's Health (AWH) just unveiled an update. Aspira Women's Health Inc. welcomes John Ragard to its Board of Directors, effective July 25, ...

Aspira Women's Health Appoints John Ragard to Board

Aspira Women's Health GAAP EPS of -$0.28 beats by $0.02, revenue of $2.4M misses by $0.2M

Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aspira Womens Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/awh-stock-quote/">AWH</a>) just reported results for the second quarter of 2024.<ul><li>Aspira Womens Health reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -30 cents.</li><li>The company reported revenue of $2.42 million.</li><li>This was 6.81% worse than the analyst estimate for revenue of $2.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/awh-stock-earnings-aspira-womens-health-for-q2-of-2024/">AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q2 2024

Aspira Women's Health ( ($AWH) ) has shared an update. Aspira Women's Health Inc. recently shared a presentation with investors, offering insights ...

Aspira Women's Health Engages Investors with Performance Insights

Press Releases

Aspira Women's Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights

Management

Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

Aspira Women's Health Announces Poster Presentation at the Menopause Society's 2024 Annual Meeting

Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference

Aspira Women's Health Reports Second Quarter 2024 Financial Results

Aspira Women's Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses

Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aspira Women's Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass

Alliance Global Partners

Cantor Fitzgerald

Comments

Aspira Womens Health

Noticias

Últimas noticias sobre Aspira Womens Health (NASDAQ:AWH) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL